Abacus Global Management, Inc. (ABX) is an Orlando, Florida-based alternative asset manager built around longevity-based assets, operating through asset management, life-solutions, and technology-services segments that buy, trade, and securitize life insurance policies while managing third-party longevity funds. In the opening hour of the November 17 session, the shares traded at $7.14, down 17.46% from the previous session's close of $8.65, a decline of $1.51 per share that cut market capitalization from roughly $845 million to about $698 million. Direction is unambiguously negative. No verified news catalyst, filing, or downgrade was found to explain the gap; the move is best described as a technical breakdown within an already fragile post-earnings trend.
No verified news or fundamental catalyst found. No press release, SEC filing, analyst rating change, or corporate announcement surfaced ahead of the open that would plausibly justify a double-digit gap, and the company's only recent disclosure was a routine November 11 notice of upcoming conference participation.
The evidence points instead to a liquidity-driven breakdown, likely amplified by the stock's thin float and heavy insider ownership. The shares gapped from $8.65 to an opening print of $7.29 and traded as low as $7.11 within minutes, a pattern consistent with a single sizable sell order hitting a shallow order book rather than a broad reassessment of fundamentals. The move is also roughly eight times the stock's typical daily swing of about 2%, which is the signature of an air pocket rather than ordinary repositioning.
The weakness did not begin today. Since reporting third-quarter results after the close on November 5, the stock has surrendered a rally that had carried it from $7.85 on October 19 to $9.13 on November 10. The quarter itself was solid — revenue of $76.9 million rose 22% year over year, adjusted EPS of $0.29 edged past the $0.28 consensus, and management raised full-year 2026 adjusted EPS guidance to $1.05–$1.07 — but the fourth-quarter guidance range of $0.28–$0.30 fell short of the $0.31 consensus, and the market has treated the print as a sell-the-news event.
Analyst sentiment remains split. The consensus rating among covering analysts is Buy with an average 12-month target of $13.75, yet at least one firm has moved the other way, cutting its target to $10 from $12 with a Neutral rating. The company has also authorized a $100 million share repurchase program and lifted its annual dividend 10% to $0.22 per share, measures that have so far failed to arrest the drift.
The decline is idiosyncratic rather than sector-driven. With a five-year beta of just 0.07, the shares have almost no statistical relationship to broad index moves, and the gap occurred as a single-stock repricing rather than a peer-group sell-off. Average daily volume over the past three months is roughly 573,000 shares, and early turnover on the tape suggested participation at or above that pace, though a full-session comparison is not yet available.
Technically, the damage is significant. The opening gap broke beneath the $7.71–$7.85 support zone that had held through mid-October and below the rising sequence of November lows, placing the stock at its lowest level in more than three months and roughly 43% below its 52-week high of $12.44. The 52-week low of $5.57 now becomes the reference point for longer-term holders.
The scale runs from 0, meaning no meaningful news and a move that is normal for the stock, to 100, meaning transformative news and an extreme, rare price move. ABX scores 46 out of 100. Verified news strength was minimal: nothing material was published before the bell, so the fundamental component is weak relative to the company's roughly $700 million market value.
The price move, by contrast, was highly unusual. At 17.46%, it was about 8.5 times the stock's average absolute daily change of roughly 2.0% over the past 60-plus sessions, and no session in that window produced a comparable decline — the largest prior move was under 9%. An extreme outlier without a verified catalyst lands the composite in the mid-40s.
The next hard catalyst is the December 1 ex-dividend date for the $0.22 annual payout, followed by fourth-quarter results in early 2027, when investors will test whether the $0.28–$0.30 adjusted EPS guide proves conservative. Management's conference appearances and any incremental 8-K disclosures on securitization activity or fund flows will be scrutinized for signs that the longevity-fund momentum — nearly $1 billion of year-to-date inflows — is intact. Sector developments around life-settlement regulation and interest rates matter given the firm's rate-sensitive balance sheet. Key risks include execution on mortality assumptions, leverage of about 0.9 times equity, limited float, and the possibility that further selling emerges before the buyback can absorb supply.
Tickeron's Trending AI Robots page highlights a curated selection drawn from hundreds of AI trading bots covering thousands of tickers. Rather than listing the full catalog, it surfaces only the strategies performing strongest under current market conditions, spanning varied approaches, timeframes, performance metrics, and traded symbols. For traders navigating volatile single names, it offers a practical starting point for comparing live strategy behavior. Explore the page to see which bots are leading right now.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
The RSI Indicator for ABX moved out of oversold territory on October 15, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 11 similar instances when the indicator left oversold territory. In 8 of the 11 cases the stock moved higher. This puts the odds of a move higher at 73%.
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on ABX as a result. In 64 of 102 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 63%.
ABX moved above its 50-day moving average on November 04, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for ABX crossed bullishly above the 50-day moving average on November 09, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 71%.
Following a +3.99% 3-day Advance, the price is estimated to grow further. Considering data from situations where ABX advanced for three days, in 146 of 208 cases, the price rose further within the following month. The odds of a continued upward trend are 70%.
The Aroon Indicator entered an Uptrend today. In 95 of 213 cases where ABX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 45%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 26 of 58 cases where ABX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 45%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ABX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 78%.
ABX broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Price Growth Rating for this company is 44 (best 1 - 100 worst), indicating steady price growth. ABX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 80 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.975) is normal, around the industry mean (1.337). P/E Ratio (30.276) is within average values for comparable stocks, (19.773). Projected Growth (PEG Ratio) (0.030) is also within normal values, averaging (0.463). Dividend Yield (0.024) settles around the average of (0.047) among similar stocks. ABX's P/S Ratio (3.453) is very high in comparison to the industry average of (1.303).
The Tickeron PE Growth Rating for this company is 96 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ABX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 61, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a mines and an explorer for gold
Industry LifeHealthInsurance